Physician profile
Peter Perdik
NPI 1760429294
$10,017.55
in general payments reported to CMS, 2019-2025
31 companies · $695 in 2025
The $695 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,686 · 2020: $1,576 · 2021: $2,921 · 2022: $1,297 · 2023: $550 · 2024: $293 · 2025: $695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,438 · Education: $98.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,438.34 |
| Education | $98.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,738.34 | 2019-2024 | Arexvy, Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals Lp | $2,358.88 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,759.97 | 2019-2022 | |
| Amgen INC. | $554.41 | 2019-2023 | Repatha, Otezla |
| Genentech USA, INC. | $462.42 | 2019-2020 | |
| Welch Allyn | $355.82 | 2019 | |
| Pfizer INC. | $233.42 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $189.74 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $185.79 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $137.87 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $98.99 | 2025 | |
| Philips North America LLC | $88.73 | 2019-2021 | |
| Novo Nordisk INC | $75.76 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $73.18 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $72.49 | 2020-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $65.62 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $65.18 | 2021 | |
| Genzyme Corporation | $62.61 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $62.39 | 2019 | |
| Jazz Pharmaceuticals INC. | $57.43 | 2019-2021 | |
| Lilly USA, LLC | $46.03 | 2019-2022 | |
| Allergan, INC. | $45.99 | 2020 | |
| Janssen Pharmaceuticals, INC | $39.59 | 2019-2021 | |
| Abbvie INC. | $36.88 | 2019-2021 | |
| Nevro Corp. | $32.87 | 2022 | |
| Insmed, INC. | $31.58 | 2021 | |
| Althera Pharmaceuticals LLC | $23.51 | 2022 | |
| Abbott Laboratories | $19.68 | 2022 | |
| Arbor Pharmaceuticals, INC. | $15.89 | 2021 | |
| Eisai INC. | $14.66 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $11.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Perdik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.